Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 5/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946820 | 0.81 | NOTCH1 (0.33) | CCKAR | |
| SCHEMBL3594079 | 0.78 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3582955 | 0.78 | BDKRB1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4186888 | 0.74 | XIAP (0.41) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13502691 | 0.72 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3589772 | 0.71 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3581234 | 0.71 | CCKBR (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13675304 | 0.70 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6954236 | 0.70 | CCKAR (0.38) | BDKRB1CCKAR | |
| SCHEMBL13502692 | 0.70 | PSEN1 (0.50) | XIAPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | claimed |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-06 | — | — | US | claimed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | claimed |
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-06-22 | — | — | US | claimed |
| US-7053081-B2 | Cyclic malonamides as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | claimed |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | OLSON RICHARD E (US) | 2005-01-13 | — | — | US | claimed |
| US-6759404-B2 | INHIBITING GAMMA-SECRETASE ACTIVITY; TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID PRODUCTION, SUCH AS ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | claimed |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | claimed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-06-22 | — | — | US | disclosed |
| US-7053081-B2 | Cyclic malonamides as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | OLSON RICHARD E (US) | 2005-01-13 | — | — | US | disclosed |
| US-6759404-B2 | INHIBITING GAMMA-SECRETASE ACTIVITY; TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID PRODUCTION, SUCH AS ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | APP, BACE1, APBA1 | XIAP 1469/4885PSEN1 6/4885PSEN2 9/4885 |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | APP, BACE1, APH1A | XIAP 2430/4885PSEN1 6/4885PSEN2 8/4885 |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | XIAP 2278/4885PSEN1 6/4885PSEN2 9/4885 |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | APP, BACE1, APBA1 | XIAP 2278/4885PSEN1 6/4885PSEN2 9/4885 |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | XIAP 1957/4885PSEN1 6/4885PSEN2 8/4885 |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | APP, BACE1, APH1A | XIAP 3168/4885PSEN1 6/4885PSEN2 8/4885 |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | APP, APBA1, APH1A | XIAP 2383/4885PSEN1 6/4885PSEN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.